Immune Thrombocytopenia natural history, complications and prognosis: Difference between revisions
Jump to navigation
Jump to search
Homa Najafi (talk | contribs) (Created page with "__NOTOC__ {{Xyz}} {{CMG}}; {{AE}} ==Overview== If left untreated, [#]% of patients with [disease name] may progress to develop [manifestation 1], [manifestation 2], and [ma...") |
(overview completed) |
||
| (3 intermediate revisions by 2 users not shown) | |||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{ | {{Immune Thrombocytopenia}} | ||
{{CMG}}; {{AE}} | {{CMG}}; {{AE}} {{Maryam}} | ||
==Overview== | ==Overview== | ||
The symptoms of chronic immune thrombocytopenia usually develop in the any decade of life, many patients are asymptomatic however about two third of patients start with symptoms such as mucocutaneous , gastrointestinal and genitourinary bleeding. Prognosis is generally excellent/good/poor, and the 5-10-year mortality rate of patients with ITP is approximately 22-34% respectfully. | |||
If left untreated, [#]% of patients with [disease name] may progress to develop [manifestation 1], [manifestation 2], and [manifestation 3]. | If left untreated, [#]% of patients with [disease name] may progress to develop [manifestation 1], [manifestation 2], and [manifestation 3]. | ||
| Line 17: | Line 19: | ||
===Natural History=== | ===Natural History=== | ||
*The symptoms of | |||
*The symptoms of (disease name) typically develop ___ years after exposure to ___. | *The symptoms of chronic immune thrombocytopenia usually develop in the any decade of life, many patients are asymptomatic however about two third of patients start with symptoms such as mucocutaneous , gastrointestinal and genitourinary bleeding.<ref>{{cite journal|doi=10.2147/JBM.S289390.}}</ref><ref name="KohliChaturvedi2019">{{cite journal|last1=Kohli|first1=Rahil|last2=Chaturvedi|first2=Shruti|title=Epidemiology and Clinical Manifestations of Immune Thrombocytopenia|journal=Hämostaseologie|volume=39|issue=03|year=2019|pages=238–249|issn=0720-9355|doi=10.1055/s-0039-1683416}}</ref> | ||
*The symptoms of (disease name) typically develop ___ years after exposure to ___. | |||
*If left untreated, [#]% of patients with [disease name] may progress to develop [manifestation 1], [manifestation 2], and [manifestation 3]. | *If left untreated, [#]% of patients with [disease name] may progress to develop [manifestation 1], [manifestation 2], and [manifestation 3]. | ||
===Complications=== | ===Complications=== | ||
*Common complications of | |||
** | *Common complications of immune thrombocytopenia include: | ||
** | **Thromboembolic risk ( the risk of thromboembolism, in ITP is twice higher than general population.) | ||
**Infection ( due to splenectomy or immunosuppressive medications) | |||
**[Complication 3] | **[Complication 3] | ||
===Prognosis=== | ===Prognosis=== | ||
*Prognosis is generally excellent/good/poor, and the | |||
*Prognosis is generally excellent/good/poor, and the 5-10-year mortality rate of patients with ITP is approximately 22-34% respectfully.<ref name="KohliChaturvedi20192">{{cite journal|last1=Kohli|first1=Rahil|last2=Chaturvedi|first2=Shruti|title=Epidemiology and Clinical Manifestations of Immune Thrombocytopenia|journal=Hämostaseologie|volume=39|issue=03|year=2019|pages=238–249|issn=0720-9355|doi=10.1055/s-0039-1683416}}</ref> | |||
*Depending on the extent of the [tumor/disease progression] at the time of diagnosis, the prognosis may vary. However, the prognosis is generally regarded as poor/good/excellent. | *Depending on the extent of the [tumor/disease progression] at the time of diagnosis, the prognosis may vary. However, the prognosis is generally regarded as poor/good/excellent. | ||
*The presence of [characteristic of disease] is associated with a particularly [good/poor] prognosis among patients with [disease/malignancy]. | *The presence of [characteristic of disease] is associated with a particularly [good/poor] prognosis among patients with [disease/malignancy]. | ||
Latest revision as of 14:43, 8 March 2021
|
Immune Thrombocytopenia Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Immune Thrombocytopenia natural history, complications and prognosis On the Web |
|
American Roentgen Ray Society Images of Immune Thrombocytopenia natural history, complications and prognosis |
|
FDA on Immune Thrombocytopenia natural history, complications and prognosis |
|
CDC on Immune Thrombocytopenia natural history, complications and prognosis |
|
Immune Thrombocytopenia natural history, complications and prognosis in the news |
|
Blogs on Immune Thrombocytopenia natural history, complications and prognosis |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Maryam Barkhordarian, M.D.[2]
Overview
The symptoms of chronic immune thrombocytopenia usually develop in the any decade of life, many patients are asymptomatic however about two third of patients start with symptoms such as mucocutaneous , gastrointestinal and genitourinary bleeding. Prognosis is generally excellent/good/poor, and the 5-10-year mortality rate of patients with ITP is approximately 22-34% respectfully.
If left untreated, [#]% of patients with [disease name] may progress to develop [manifestation 1], [manifestation 2], and [manifestation 3].
OR
Common complications of [disease name] include [complication 1], [complication 2], and [complication 3].
OR
Prognosis is generally excellent/good/poor, and the 1/5/10-year mortality/survival rate of patients with [disease name] is approximately [#]%.
Natural History, Complications, and Prognosis
Natural History
- The symptoms of chronic immune thrombocytopenia usually develop in the any decade of life, many patients are asymptomatic however about two third of patients start with symptoms such as mucocutaneous , gastrointestinal and genitourinary bleeding.[1][2]
- The symptoms of (disease name) typically develop ___ years after exposure to ___.
- If left untreated, [#]% of patients with [disease name] may progress to develop [manifestation 1], [manifestation 2], and [manifestation 3].
Complications
- Common complications of immune thrombocytopenia include:
- Thromboembolic risk ( the risk of thromboembolism, in ITP is twice higher than general population.)
- Infection ( due to splenectomy or immunosuppressive medications)
- [Complication 3]
Prognosis
- Prognosis is generally excellent/good/poor, and the 5-10-year mortality rate of patients with ITP is approximately 22-34% respectfully.[3]
- Depending on the extent of the [tumor/disease progression] at the time of diagnosis, the prognosis may vary. However, the prognosis is generally regarded as poor/good/excellent.
- The presence of [characteristic of disease] is associated with a particularly [good/poor] prognosis among patients with [disease/malignancy].
- [Subtype of disease/malignancy] is associated with the most favorable prognosis.
- The prognosis varies with the [characteristic] of tumor; [subtype of disease/malignancy] have the most favorable prognosis.
References
- ↑ . doi:10.2147/JBM.S289390. Check
|doi=value (help). Missing or empty|title=(help) - ↑ Kohli, Rahil; Chaturvedi, Shruti (2019). "Epidemiology and Clinical Manifestations of Immune Thrombocytopenia". Hämostaseologie. 39 (03): 238–249. doi:10.1055/s-0039-1683416. ISSN 0720-9355.
- ↑ Kohli, Rahil; Chaturvedi, Shruti (2019). "Epidemiology and Clinical Manifestations of Immune Thrombocytopenia". Hämostaseologie. 39 (03): 238–249. doi:10.1055/s-0039-1683416. ISSN 0720-9355.